Clinical Trials Logo
  1. Home
  2. Locally Advanced Lung Carcinoma
  3. NCT04680377

Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients — Microdurva  

NSCLC, Stage III Clinical Trial

Official title:
Using Microbiome to Predict Durvalumab Toxicity in Post-CCRT NSCLC Patients (Microdurva)

Clinical Trial Summary

This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04680377
Study type Observational
Source University of Kansas Medical Center
Contact KUCC Navigation
Phone 9135883671
Email kucc_Navigation@kumc.edu
Status Recruiting
Phase
Start date April 12, 2021
Completion date December 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05386888 - A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC Phase 2
Recruiting NCT05128630 - Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. Phase 2
Active, not recruiting NCT05027165 - Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
Recruiting NCT05311709 - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities Phase 2
Recruiting NCT04351256 - Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy Phase 2
Active, not recruiting NCT04392505 - Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study Phase 2
Recruiting NCT05611879 - Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC Phase 2
Recruiting NCT05718297 - Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT06467383 - A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
Recruiting NCT04952168 - Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC Phase 2
Recruiting NCT04830826 - A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
Recruiting NCT05757843 - Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab Phase 2
Active, not recruiting NCT03999710 - Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer Phase 2
Recruiting NCT03454685 - The Role of Microbiota on the Development of Lung Cancer
Not yet recruiting NCT05177497 - SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC Phase 2
Recruiting NCT04202809 - Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. Phase 2
Recruiting NCT04585490 - Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC Phase 3
Recruiting NCT04654364 - Lung Cancer Registry
Recruiting NCT05344209 - Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer Phase 2
Withdrawn NCT03130829 - To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC N/A